Mass Spectrometry Based Serum Glycoproteomics

David Morgenstern, 234 Hertzel St, Weizmann institute, Rehovot, Israel (david.morgenstern@weizmann.ac.il)
Alexandra Gabashvili, 234 Hertzel St, Weizmann Institute, Rehovot, Israel
Dalia Elinger, 234 Hertzel St, Weizmann Institute, Rehovot, Israel
Yishai Levin, 234 Hertzel St, Weizmann Institute, Rehovot, Israel

Enter the body of yoAnalysis of glycan carrying proteins receives increasing interest in biomedical research. Specifically, there is a growth in the application of glycoproteins and their glycan composition as biomarkers and biotheraputics for various diseases such as cancer and heart failure. Despite significant advances in data acquisition and data analysis for the glycoproteomics, this post-translational modificaiton still poses significant analytical and computational challenges. Glycosylations may account for more than 5% of the modified peptides in the proteome, but the wide variability in glycan composition reduces the abundance of individual glycan compositions almost below detection threshold, requiring the use of enrichment before global analysis of glycopeptides and proteins. Unfortunately, the enrichment strategies for glycopeptides/glycoproteins are not very efficient. The use of naturally occurring glycan-binding proteins (lectins) leads to highly specific enrichment. Enrichment using HILIC fractionation is not efficient or specific enough and is biased against small glycans and hydrophobic peptides, while the promise of boronic acid as a non-biased enrichment strategy is yet to materialize. 

Here we present screening of 21 different lectins screened against the human serum proteome, to determine the optimal combination of lectins for global coverage of the serum glycoproteome. Furthermore, we present a unique capability of extensively investigating both the N- and O- serum glycoproteome.

 

---

Short Biography of Presenting Author

I am currently holding the position of Staff Scientist at the de Botton Institute for Protein Profiling. The Nancy and Stephen Grand Israel National Center for Personalized Medicine at the Weizmann Institute. I have received my PhD from the University of Queensland's Institute for Molecular Biosciences and further trained in "fringe" proteomics at NYU medical center's Proteomics Center. 

I am experienced in multiple -omics, including genomics and metabolomics, but specialize in Protoemics. Specifically, glycoproteomics, Top-Down proteomics and de-novo sequencing.